The New GlaxoSmithKline (GSK) To Be Unveilied on 6/23 - Morgan Stanley

June 16, 2021 9:10 AM EDT
Get Alerts GSK Hot Sheet
Price: $39.50 --0%

Rating Summary:
    8 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 3 | Down: 5 | New: 8
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Morgan Stanley analyst Mark Purcell reiterated an Equalweight rating on GlaxoSmithKline (NYSE: GSK) ahead of June 23rd when GSK will lay out its vision for the new Biopharma business post the CHC separation.

The analyst believes that "new 5-year targets could provide upside to consensus earnings in 2026,
but incremental progress in innovation and limited long-term visibility suggest GSK could remain a 'show me' story."

For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.

Shares of GlaxoSmithKline closed at $40.57 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Morgan Stanley, Earnings